Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 15251 - 15275 of 15491 in total
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
AGI-1096 is a novel oral antioxidant and selective anti-inflammatory agent that is being developed to address the accelerated inflammation of grafted blood vessels, known as transplant arteritis, common in chronic organ transplant rejection.
Investigational
Matched Description: … AGI-1096 is a novel oral antioxidant and selective anti-inflammatory agent that is being developed to …
Bleximenib is under investigation in clinical trials NCT04811560 (A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia) and NCT05453903 (A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies)
Investigational
Matched Description: … in clinical trials NCT04811560 (A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia) and
MRX-I has been used in trials studying the treatment of Bacterial Infections.
Investigational
KD7040 is a topically-delivered inducible nitric oxide synthase (iNOS) inhibitor for the treatment of neuropathic pain. The KD7040 IND was filed in 4Q06, and a Phase Ib clinical trial began 2Q07. It is being developed by Kalypsys.
Investigational
Matched Description: … The KD7040 IND was filed in 4Q06, and a Phase Ib clinical trial began 2Q07. …
PF-05241328 is under investigation in clinical trial NCT01165736 (To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not Have Any Pharmacological Activity).
Investigational
Matched Description: … investigation in clinical trial NCT01165736 (To Calculate the Pharmacokinetics (Concentration of Compound in and
An alkaloid that has actions similar to nicotine on nicotinic cholinergic receptors but is less potent. It has been proposed for a variety of therapeutic uses including in respiratory disorders, peripheral vascular disorders, insomnia, and smoking cessation. [PubChem]
Investigational
Matched Description: … variety of therapeutic uses including in respiratory disorders, peripheral vascular disorders, insomnia, and
Almonertinib is a third-generation EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M resistance mutations.[A231859, A231864, A231869] It is being investigated against advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC).
Investigational
Matched Description: … Almonertinib is a third-generation EGFR tyrosine kinase inhibitor targeting EGFR-sensitizing and T790M …
MK-8777 is under investigation in clinical trial NCT00610649 (Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and Tolerability, of Org 26576 in Participants With Major Depressive Disorder (174001/P05704/MK-8777-001)).
Investigational
Matched Description: … in clinical trial NCT00610649 (Trial to Determine the Maximum Tolerated Dose (MTD) Based on Safety and
Baxdrostat is under investigation in clinical trial NCT06344104 (A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Asian Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension).
Investigational
Matched Description: … is under investigation in clinical trial NCT06344104 (A Phase III Study to Investigate the Efficacy and
KER-047 is under investigation in clinical trial NCT05927012 (A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).).
Investigational
Matched Description: … KER-047 is under investigation in clinical trial NCT05927012 (A Study to Evaluate the Safety and Preliminary …
Experimental
PZM21 is a novel μ-opioid receptor (MOPr) ligand that has been reported to induce minimal arrestin recruitment and be devoid of the respiratory depressant effects characteristic of classical μ-opioid ligands such as morphine.
Experimental
Matched Description: … novel μ-opioid receptor (MOPr) ligand that has been reported to induce minimal arrestin recruitment and
An amphetamine derivative that inhibits uptake of catecholamine neurotransmitters. It is a hallucinogen. It is less toxic than its methylated derivative but in sufficient doses may still destroy serotonergic neurons and has been used for that purpose experimentally. [PubChem]
Experimental
Illicit
Matched Description: … toxic than its methylated derivative but in sufficient doses may still destroy serotonergic neurons and
AD 337 was under investigation in clinical trial NCT00377039 (A Multicentre Trial to Determine the Efficacy and Safety of AD-337 in the Treatment of Fibromyalgia). The drug was created by Sosei pharmaceuticals to treat Fibromyalgia in female patients.
Investigational
Matched Description: … was under investigation in clinical trial NCT00377039 (A Multicentre Trial to Determine the Efficacy and
AI-128 is the first human demonstration of sustained release drug administration in the lung. AI-128 consists of slowly dissolving microspheres designed to control where drug particles go in the lung and how quickly they release their drug.
Investigational
Matched Description: … consists of slowly dissolving microspheres designed to control where drug particles go in the lung and
Displaying drugs 15251 - 15275 of 15491 in total